Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2001;32:2567-2574
doi: 10.1161/hs1101.098523
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sjöblom, L.
Right arrow Articles by Wallvik, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sjöblom, L.
Right arrow Articles by Wallvik, J.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Blood Thinners

(Stroke. 2001;32:2567.)
© 2001 American Heart Association, Inc.


Original Contributions

Management and Prognostic Features of Intracerebral Hemorrhage During Anticoagulant Therapy

A Swedish Multicenter Study

Lars Sjöblom, MD; Hans-Göran Hårdemark, MD, PhD; Arne Lindgren, MD, PhD; Bo Norrving, MD, PhD; Martin Fahlén, MD, PhD; Margareta Samuelsson, MD, PhD; Lennart Stigendal, MD, PhD; Dick Stockelberg, MD, PhD; Ali Taghavi, MD; Lena Wallrup, MD Jonas Wallvik, MD, PhD

From the Departments of Internal Medicine (L.S.) and Neurology (H.-G.H.) at Uppsala University Hospital, Uppsala; the Department of Neurology at Lund University Hospital (A.L., B.N.), Lund, and Örebro University Hospital (M.S.), Örebro; and the Departments of Internal Medicine at Kungälv Hospital (M.F.), Kungälv, Sahlgrenska University Hospital (L.S., D.S.), Göteborg, Mölndal Hospital (A.T.), Mölndal, Falu Hospital (L.W.), Falu, and Sundsvall Hospital (J.W.), Sundsvall, Sweden.

Correspondence to Hans-Göran Hårdemark, MD, PhD, Department of Neurology, Center of Clinical Neurosciences, University Hospital, S 751 85 Uppsala, Sweden. E-mail H-G.Hardemark{at}neurologi.uu.se

Background and Purpose— Patients treated with oral anticoagulants (ACs) have an increased risk of intracerebral hemorrhage (ICH), which is more often fatal than spontaneous ICH. Options to reverse the AC effect include intravenous administration of vitamin K, plasma, and coagulation factor concentrate. However, the optimal management of AC-related ICH has not been determined in any randomized trial. In this study, the present management of AC-related ICH was surveyed, and determinants of survival were assessed.

Methods— We retrospectively reviewed the medical records of all AC-related ICHs at 10 Swedish hospitals during a 4-year period, 1993 to 1996. Survival status after the ICH was determined from the Swedish National population register.

Results— We identified 151 patients with AC-related ICH. Death rates were 53.6% at 30 days, 63.6% at 6 months, and 77.5% at follow-up (mean 3.5 years). The case fatality ratio at 30 days was 96% among patients unconscious on admission (n=27), 80% among patients who became unconscious before active treatment was started (n=15), 55% among patients in whom no special action was taken except withdrawal of AC treatment (n=42), and 28% among patients given active anti-coumarin treatment while they were still conscious (n=64). The case fatality ratio at 30 days was 11% in the group treated with plasma (n=18), 30% in the group treated with vitamin K (n=23), and 39% in the group treated with coagulation factor concentrate (n=23). Within the first 24 to 48 hours after admission, 47% of the patients deteriorated. Choice of therapy to reverse the AC effect differed substantially between the hospitals (P<0.0001), as did the time interval from symptom onset to start of treatment. Multiple logistic regression analysis showed only 2 factors (intraventricular extension of bleeding and ICH volume) that were independently related to case fatality at both 30 days and 6 months. The results were similar when the analysis was restricted to patients who were conscious on admission.

Conclusions— In AC-related ICH, a progressive neurological deterioration during the first 24 to 48 hours after admission is frequent, and the mortality is high. Choice of therapy to reverse the AC effect differed considerably between the hospitals. There was no evidence that any treatment strategy was superior to the others. A randomized controlled trial is needed to determine the best choice of treatment.


Key Words: anticoagulants • cerebral hemorrhage • prognosis • tomography, x-ray computed




This article has been cited by other articles:


Home page
StrokeHome page
M. L. Flaherty, O. Adeoye, P. Sekar, M. Haverbusch, C. J. Moomaw, H. Tao, J. P. Broderick, and D. Woo
The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage
Stroke, May 1, 2009; 40(5): 1738 - 1742.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
C. Foerch, K. Arai, G. Jin, K.-P. Park, S. Pallast, K. van Leyen, and E. H. Lo
Experimental Model of Warfarin-Associated Intracerebral Hemorrhage
Stroke, December 1, 2008; 39(12): 3397 - 3404.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. Cucchiara, S. Messe, L. Sansing, S. Kasner, P. Lyden, and for the CHANT Investigators
Hematoma Growth in Oral Anticoagulant Related Intracerebral Hemorrhage
Stroke, November 1, 2008; 39(11): 2993 - 2996.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al.
REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Circulation, October 16, 2007; 116(16): e391 - e413.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
K. M. Thompson, S. Y. Gerlach, H. K. S. Jorn, J. M. Larson, T. G. Brott, and J. A. Files
Advances in the Care of Patients With Intracerebral Hemorrhage
Mayo Clin. Proc., August 1, 2007; 82(8): 987 - 990.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al.
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Stroke, June 1, 2007; 38(6): 2001 - 2023.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. N. Goldstein, L. E. Fazen, R. Snider, K. Schwab, S. M. Greenberg, E. E. Smith, M. H. Lev, and J. Rosand
Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage
Neurology, March 20, 2007; 68(12): 889 - 894.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
A. A. Rabinstein and E. F. M. Wijdicks
Determinants of Outcome in Anticoagulation-Associated Cerebral Hematoma Requiring Emergency Evacuation
Arch Neurol, February 1, 2007; 64(2): 203 - 206.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
M. I. Aguilar, R. G. Hart, C. S. Kase, W. D. Freeman, B. J. Hoeben, R. C. Garcia, J. E. Ansell, S. A. Mayer, B. Norrving, J. Rosand, et al.
Treatment of Warfarin-Associated Intracerebral Hemorrhage: Literature Review and Expert Opinion
Mayo Clin. Proc., January 1, 2007; 82(1): 82 - 92.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. B. Huttner, P. D. Schellinger, M. Hartmann, M. Kohrmann, E. Juettler, J. Wikner, S. Mueller, U. Meyding-Lamade, R. Strobl, U. Mansmann, et al.
Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant Therapy: Comparison of Acute Treatment Strategies Using Vitamin K, Fresh Frozen Plasma, and Prothrombin Complex Concentrates
Stroke, June 1, 2006; 37(6): 1465 - 1470.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. E. Gerber, S. A. Grossman, and M. B. Streiff
Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
J. Clin. Oncol., March 10, 2006; 24(8): 1310 - 1318.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. Alemany, A. Stenborg, A. Terent, P. Sonninen, and R. Raininko
Coexistence of Microhemorrhages and Acute Spontaneous Brain Hemorrhage: Correlation with Signs of Microangiopathy and Clinical Data
Radiology, January 1, 2006; 238(1): 240 - 247.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. C. Hemphill III
Treating Warfarin-Related Intracerebral Hemorrhage: Is Fresh Frozen Plasma Enough?
Stroke, January 1, 2006; 37(1): 6 - 7.
[Full Text] [PDF]


Home page
StrokeHome page
T. Steiner, J. Rosand, and M. Diringer
Intracerebral Hemorrhage Associated With Oral Anticoagulant Therapy: Current Practices and Unresolved Questions
Stroke, January 1, 2006; 37(1): 256 - 262.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
W. D. Freeman, T. G. Brott, K. M. Barrett, P. R. Castillo, H. G. Deen Jr, L. F. Czervionke, and J. F. Meschia
Recombinant Factor VIIa for Rapid Reversal of Warfarin Anticoagulation in Acute Intracranial Hemorrhage
Mayo Clin. Proc., December 1, 2004; 79(12): 1495 - 1500.
[Abstract] [PDF]


Home page
J. Clin. Pathol.Home page
J P Hanley
Warfarin reversal
J. Clin. Pathol., November 1, 2004; 57(11): 1132 - 1139.
[Abstract] [Full Text] [PDF]